Empyrean Capital Partners LP Takes $14.40 Million Position in Teleflex Incorporated $TFX

Empyrean Capital Partners LP purchased a new stake in Teleflex Incorporated (NYSE:TFX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 118,000 shares of the medical technology company’s stock, valued at approximately $14,401,000. Empyrean Capital Partners LP owned approximately 0.27% of Teleflex as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of TFX. Banque Cantonale Vaudoise boosted its holdings in shares of Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after buying an additional 113 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Teleflex in the 4th quarter valued at about $37,000. UMB Bank n.a. boosted its holdings in shares of Teleflex by 57.1% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after buying an additional 113 shares in the last quarter. Sound Income Strategies LLC bought a new stake in shares of Teleflex in the 4th quarter valued at about $45,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of Teleflex in the 4th quarter valued at about $45,000. 95.62% of the stock is currently owned by institutional investors.

Teleflex Stock Down 2.2%

TFX stock opened at $125.08 on Thursday. The firm has a 50 day moving average of $129.31 and a 200 day moving average of $119.24. The stock has a market capitalization of $5.54 billion, a PE ratio of -5.49, a price-to-earnings-growth ratio of 0.95 and a beta of 0.82. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. Teleflex Incorporated has a 52 week low of $100.18 and a 52 week high of $139.67.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. Teleflex’s revenue for the quarter was up 32.3% on a year-over-year basis. During the same period last year, the business earned $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Sell-side analysts forecast that Teleflex Incorporated will post 6.7 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Monday, May 25th will be paid a $0.34 dividend. The ex-dividend date is Friday, May 22nd. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex’s dividend payout ratio (DPR) is -5.96%.

Analyst Ratings Changes

TFX has been the topic of a number of recent analyst reports. Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $135.00 to $155.00 in a report on Friday, May 8th. Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target on the stock in a report on Monday, April 13th. Wall Street Zen cut shares of Teleflex from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research upgraded shares of Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $146.00.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.